

FINAL PROGRAMME



FIVE NATIONS CONFERENCE

on

HIV and Hepatitis

8–9 December 2014

Queen Elizabeth II Conference Centre

LONDON · UK



in partnership
with



GRUPO DE ESTUDIO DE HEPATITIS
VIRICAS - SEIMC



12 CPD Credits
Unique Reference No:
90148



C O N T E N T S

Programme Summary	3	Sponsors and Exhibitors	12
Pre-conference Programme	4,5	Exhibition Floor Plan	13
Conference Programme	6–9	Committee & Partner Organisations	14
Programme of Satellite Symposia	10	Biographies	15
Conference Information	11		

Dear Delegate

Welcome to the inaugural **Five Nations Conference on HIV and Hepatitis** in London, UK. The Conference has been led by a Programme Committee comprising representatives from all partner organisations from France, Germany, Italy, Spain and the UK.

I would like to extend my grateful thanks to the Committee Members for their efforts in preparing an excellent programme for this conference.

We are especially delighted that a number of eminent international speakers are joining us in London to share their latest research and we thank them for their invaluable contributions in helping to make the conference, what promises to be, a great success.

Finally, we would like to thank our sponsors for their support, which assists greatly with the costs incurred in organising this conference.

We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Yours sincerely,

Dr Ranjababu Kulasegaram

Chair, Five Nations Conference Steering Committee



FIVE NATIONS CONFERENCE ON HIV AND HEPATITIS

QUEEN ELIZABETH II CONFERENCE CENTRE · BROAD SANCTURY · LONDON SW10 3EE

Registration	Sanctuary Foyer, Ground Floor
Pre-conference Clinical Course	Churchill Auditorium, Ground Floor
Pre-conference Nurses' Course	Caxton East Room, Second Floor
Five Nations Conference	
▶ Lecture Theatre	Churchill Auditorium, Ground Floor
▶ Lunchtime Workshops	Caxton East Room, Second Floor
▶ Satellite Symposia	Churchill Auditorium, Ground Floor
▶ Exhibition	Pickwick Suite, First Floor
▶ Lunch and Refreshments	Pickwick Suite, First Floor
▶ Speakers' Presentation Preview Room	Control Room, First Floor
▶ Welcome Reception	Pickwick Suite, First Floor

12 CPD Credits

Unique reference number: **90148**



M O N D A Y 8 D E C E M B E R

0900–1930	Registration open at QEII Conference Centre
0925–1200	Pre-conference Clinical Course
0925–1200	Pre-conference Nurses' Course

FIVE NATIONS CONFERENCE

1145–1930	Exhibition open at the QEII Conference Centre
1145–1230	Lunch
1230–1245	Introduction
1245–1345	Janssen Satellite Symposium
1345–1435	Plenary Session 1
1435–1500	Afternoon tea
1500–1545	Clinical case presentations
1545–1615	Invited Lecture 1
1615–1715	Plenary Session 2
1715–1730	Refreshments
1730–1800	Invited Lecture 2
1800–1900	Gilead Sciences Satellite Symposium
1900–1930	Welcome Reception

T U E S D A Y 9 D E C E M B E R

0800–1410	Registration and Exhibition open at QEII Conference Centre
0800–0830	Breakfast <i>supported by AbbVie</i>
0830–0930	AbbVie Satellite Symposium
0930–1035	Plenary Session 3
1035–1100	Morning coffee
1100–1200	Plenary Session 4
1200–1300	Plenary Session 5
1300–1410	Lunch and exhibition
1310–1355	Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop
1410–1500	What is in the pipeline?
1500–1615	Plenary Session 6
1615–1655	Two debates
1655–1700	Close





M O N D A Y 8 D E C E M B E R

PRE-CONFERENCE CLINICAL COURSE

SESSIONS TO BE HELD IN THE CHURCHILL AUDITORIUM, GROUND FLOOR

0900–1200 *Registration open at QEII Conference Centre*

0925–0930 **Welcome Address**

Chairs: Dr Sanjay Bhagani, *Royal Free Hospital, London, UK*

Professor Karine Lacombe, *Hôpital Saint-Antoine, Paris, France*

0930–0955 **The history and basics of HCV virology**

Professor Carlo-Federico Perno, *University of Rome 'Tor Vergata', Italy*

0955–1020 **Clinical evaluation of HCV-induced liver disease**

Professor Karine Lacombe, *Hôpital Saint-Antoine, Paris, France*

1020–1045 **The impact of HIV on hepatitis C and vice versa**

Dr Sanjay Bhagani, *Royal Free Hospital, London, UK*

1045–1110 *Morning coffee*

1110–1135 **Treatment of hepatitis C: who, when and how**

Dr Patrick Ingiliz, *Medical Center for Infectious Diseases, Berlin (MIB), Germany*

Panel:

Mr Siegfried Schwarze, *Medical European AIDS Treatment Group (EATG)*

1135–1200 **End-stage liver disease and its complications**

Professor Graham Foster, *Queen Mary University of London, UK*

Pre-conference Clinical Course
is sponsored by



Bristol-Myers Squibb

Bristol-Myers Squibb has supported this Pre-conference Clinical Course by purchasing exhibition stand space and delegate places and has had no input into the selection of speakers or topics



M O N D A Y 8 D E C E M B E R

PRE-CONFERENCE NURSES' COURSE

SESSIONS TO BE HELD IN THE CAXTON EAST ROOM, SECOND FLOOR

0900–1200 *Registrations open at QEII Conference Centre*

0925–0930 **Welcome Address**

Chairs: Ms Michelle Croston, National HIV Nurses Association (NHIVNA)

Ms Fiona Fry, Chair, British Association for the Study of the Liver Nurse Forum (BASLNF)

0930–0955 **Understanding the hepatitis C virus: a nurse perspective**

Mr Dean Linzey, Royal Berkshire NHS Foundation Trust, Reading, UK

0955–1020 **A guide to the anatomy and physiology of the liver**

Ms Amanda Clements, Plymouth Hospital NHS Foundation Trust, UK

1020–1045 **Introduction to blood results, interpretation and nursing priorities**

Mrs Janet Catt, Royal Free London NHS Foundation Trust, UK

1045–1110 *Morning coffee*

1110–1135 **How will new treatments affect nursing practice?**

Mr Ricky Gellissen, Imperial College Healthcare NHS Trust, London, UK

1135–1200 **What is the impact of HIV/HCV co-infection in the era of chem sex?**

Mr Joe Phillips, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK



National HIV Nurses Association

The Pre-conference Nurses' Course is organised by the National HIV Nurses Association (NHIVNA) and the British Association for the Study of the Liver Nurses' Forum (BASLNF)



Sponsors have supported this Course by purchasing exhibition stand space and delegate places and have had no input into the course programme

Pre-conference Nurses' Course
is sponsored by

abbvie

GILEAD

janssen
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

Roche Roche Products Ltd



M O N D A Y 8 D E C E M B E R

FIVE NATIONS CONFERENCE

SESSIONS TO BE HELD IN THE CHURCHILL AUDITORIUM, GROUND FLOOR

1145–1930 *Registration and Exhibition open at QEII Conference Centre*

1145–1230 Lunch

1230–1245 **Introduction and Welcome**

Dr Ranjababu Kulasegaram, *Chair, Five Nations Conference Steering Committee*

Panel

Professor Karine Lacombe, *French National Agency for AIDS Research (ANRS)*

Dr Juan Pineda, *Spanish Infectious Diseases and Clinical Microbiology Society (SEIMC)*

Professor Jürgen Rockstroh, *German AIDS Society (DAIG)*

Professor Gloria Taliani, *Italian Society of Infectious and Tropical Diseases (SIMIT)*

Dr Andrew Ustianowski, *British Association for the Study of the Liver (BASL)*

1245–1345 **Janssen Satellite Symposium**
(see page 10 for further details)

1345–1435 **Plenary Session 1**

Chairs: Dr Juan Berenguer, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*

Dr Graham Cooke, *Imperial College, London, UK*

The global challenge of HCV

Dr Isabelle Andrieux-Meyer, *Médecins Sans Frontières, Geneva, Switzerland*

The epidemiology of HIV and viral hepatitis in Europe

Professor Amanda Mocroft, *Institute of Epidemiology and Health, London, UK*

1435–1500 *Afternoon tea*

1500–1545 **Clinical case presentations**

Chairs: Dr Gary Brook, *North West London Hospitals NHS Trust, UK*

Dr Janice Main, *Imperial College Healthcare NHS Trust, London, UK*

Panel

Dr Manuel Crespo, *Vall d'Hebron Hospital, Barcelona, Spain*

Professor Lionel Piroth, *CHU Dijon, France*

Professor Massimo Puoti, *University of Brescia, Italy*

Dr Christopher Taylor, *King's College Hospital NHS Foundation Trust, London, UK*

Once, twice, three times a virus ...

Dr Binta Sultan, *Mortimer Market Centre, London, UK*

Renal impairment during triple therapy with telaprevir for chronic hepatitis C: a case report

Dr Elisa Biliotti, *Sapienza University of Rome, Italy*

Hepatitis delta is leading infection in HBV/HCV/HDV and HIV patient

Dr Ivana Carey, *King's College Hospital, London, UK*



M O N D A Y 8 D E C E M B E R

FIVE NATIONS CONFERENCE

1545–1615

Invited Lecture 1

Chair: Dr Kosh Agarwal, King's College Hospital NHS Trust, London, UK

Liver transplantation in the HIV-infected population

Professor Massimo Puoti, University of Brescia, Italy

1615–1715

Plenary Session 2

Chairs: Professor Jürgen Rockstroh, University of Bonn, Germany

Dr Andrew Ustianowski, North Manchester General Hospital, UK

Extrahepatic manifestations of HCV: from immune- to inflammation-related manifestations

Professor Patrice Cacoub, La Pitié-Salpêtrière Hospital, Paris, France

Non-alcoholic steatohepatitis (NASH)

Dr Maud Lemoine, Imperial College Healthcare NHS Trust, London, UK

1715–1730

Refreshments (Churchill Auditorium, Ground Floor)

1730–1800

Invited Lecture 2

Chair: Dr Emma Page, Leeds Teaching Hospitals Trust, UK

Hepatocellular carcinoma

Dr Nicolás Merchante, Hospital Universitario de Valme, Sevilla, Spain

1800–1900

Gilead Sciences Satellite Symposium

(see page 10 for further details)

1900–1930

Welcome Reception

Pickwick Suite, First Floor

1945–2200

Janssen Evening Seminar: The ART of HIV

One Great George Street, London

The evening seminar is not part of the formal Five Nations Conference programme, but delegates are welcome to attend. See delegate bag insert for further details.



T U E S D A Y 9 D E C E M B E R

FIVE NATIONS CONFERENCE

SESSIONS TO BE HELD IN THE CHURCHILL AUDITORIUM, GROUND FLOOR

0800–1615 *Registration and Exhibition opens at QEII Conference Centre*

0800–0830 Breakfast *sponsored by* AbbVie **abbvie**

0830–0930 **AbbVie Satellite Symposium**
(see page 10 for further details)

0930–1035 **Plenary Session 3**
Chairs: Dr Ashley Brown, Imperial College Healthcare NHS Trust, London, UK
Dr Mark Nelson, Chelsea and Westminster Hospital, London, UK
Treatment of HCV in mono-infected patients
Professor Jean-Michel Pawlotsky, Hôpital Henri Mondor, Paris, France
Treatment of HCV in co-infected patients
Professor Douglas Dieterich, Mount Sinai Medical Center, NYC, USA
Panel discussion

1035–1100 *Morning coffee*

1100–1200 **Plenary Session 4**
Chairs: Professor Francesca Ceccherini-Silberstein, University of Rome 'Tor Vergata', Italy
Dr Juan Macia, Hospital Universitario de Valme, Sevilla, Spain
What's new in hepatitis B/HIV co-infection?
Professor Vincent Soriano, Hospital Carlos III, Madrid, Spain
Will hepatitis B become a curable disease?
Dr Patrick Kennedy, The Royal London Hospital, UK

1200–1300 **Plenary Session 5**
Chairs: Dr Stefan Mauss, Centre for HIV and Hepatogastroenterology, Düsseldorf, Germany
Dr Emma Thomson, University of Glasgow, UK
Hepatitis D in HIV
Dr Kate Childs, King's College Hospital NHS Foundation Trust, London, UK
Acute hepatitis C
Dr Emma Page, Leeds Teaching Hospitals Trust, UK

1300–1410 *Lunch and exhibition*

1310–1355 **Bristol-Myers Squibb Pharmaceuticals Limited Lunchtime Workshop**
Caxton East Room, Second Floor
Lunchpacks will be provided (see page 10 for further details)



T U E S D A Y 9 D E C E M B E R

FIVE NATIONS CONFERENCE

1410–1500

What is in the pipeline?

Chairs: Professor Clifford Leen, *Western General Hospital, Edinburgh, UK*
Dr Ed Wilkins, *North Manchester General Hospital, UK*

Dr Alice Butler, *AbbVie Ltd*

Dr Adyb Baakili, *Bristol-Myers Squibb Pharmaceuticals Ltd*

Dr Cham Herath, *Gilead Sciences International Ltd*

Dr Jonty Manuja, *Janssen*

Dr Andrew Wilfin, *MSD Ltd*

1500–1615

Plenary Session 6

HIV/hepatitis in Europe: who, when and where

Chairs: Dr Ranjababu Kulasegaram

Guy's and St Thomas' NHS Foundation Trust, London, UK

Mr Brian West, *European AIDS Treatment Group (EATG)*

United Kingdom

Professor Caroline Sabin, *Royal Free and University College Medical School, London, UK*

France

Professor Lionel Piroth, *CHU Dijon, France*

Germany

Dr Christoph Boesecke, *University of Bonn, Germany*

Italy

Professor Gloria Taliani, *Sapienza University of Rome, Italy*

Spain

Dr Juan Pineda, *Hospital Universitario de Valme, Sevilla, Spain*

European AIDS Treatment Group (EATG)

Mr Diego Garcia Morcillo, *European AIDS Treatment Group (EATG), Spain*

Panel discussion

1615–1655

Two debates:

Chairs: Mr Maxime Journiac, *European AIDS Treatment Group (EATG)*

Dr Daniel Webster, *Royal Free London NHS Foundation Trust, UK*

- **Re-infections should not be retreated**

For the motion: Dr Robert James, *Birchgrove, UK*

Against the motion: Mr Luís Mendão, *European AIDS Treatment Group (EATG), Portugal*

- **F2–F3 fibrosis: treat now**

For the motion: Professor Jürgen Rockstroh, *University of Bonn, Germany*

Against the motion: Dr Mark Nelson, *Chelsea and Westminster Hospital, London, UK*

1655–1700

Close

Dr Ranjababu Kulasegaram, *Chair, Five Nations Conference Steering Committee*

Programme of Satellite Symposia and Sponsors Lunchtime Workshop



All Satellite Symposia will be held in the Churchill Auditorium, Ground Floor.
Lunchtime Workshops will be held in the Caxton East Room, Second Floor

MONDAY 8 DECEMBER

- 1245–1345 **Janssen Satellite Symposium**
HIV and hepatitis C: the patient's journey through a clinical setting
Chair: Dr Emma Page, *Leeds Teaching Hospitals NHS Trust*
Dr Laura Waters, *University College London Medical School, UK*
Dr Ed Wilkins, *North Manchester General Hospital, UK*
-
- 1800–1900 **Gilead Sciences Satellite Symposium**
Transforming HCV care: learning from the HIV journey
Defining the challenges – back to the future
Professor Jürgen Rockstroh, *University of Bonn, Germany*
Charting success – lessons learned from HIV
Professor Karine Lacombe, *Hôpital Saint-Antoine, Paris, France*
Quantum leaps forward – transforming HCV care
Dr Andrew Ustianowski, *North Manchester General Hospital, UK*
Overcoming the challenges – fast-forward to the future
Panel discussion

TUESDAY 9 DECEMBER

- 0830–0930 **AbbVie Satellite Symposium**
Striving for clarity in HIV/HCV co-infection: defining priorities via Room 101
Chair: Dr Laura Waters, *University College London Medical School, UK*
Dr Kosh Agarwal, *King's College Hospital, UK*
Dr Sanjay Bhagani, *Royal Free London NHS Foundation Trust, UK*
Dr Mark Nelson, *Chelsea and Westminster Hospital, UK*
-
- 1310–1355 **Bristol-Myers Squibb Pharmaceuticals Limited Lunchtime Workshop**
Caxton East Room, Second Floor
Lunchpacks will be provided
Cases from the clinic: New options for patients with hepatitis C
Chair: Dr Mark Nelson, *Chelsea and Westminster Hospital, London, UK*
Dr Ashley Brown, *Imperial College Healthcare NHS Trust, London, UK*
Dr Andrew Ustianowski, *North Manchester General Hospital, UK*



Registration

FIVE NATIONS CONFERENCE The registration fee gives access to the scientific sessions of the **Five Nations Conference on HIV and Hepatitis** including satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee. Registration opens from 1145 on Monday 8 December and from 0800 on Tuesday 9 December 2014.

PRE-CONFERENCE COURSES: Clinical Course and Nurses' Course Registration is on a complimentary basis. However, if you fail to turn up to the event, then your cheque or credit card will be charged £50. Registration gives access to the scientific sessions of the relevant course. Welcome and mid-morning refreshments are included. Please note that **lunch is not included** as part of registration for the courses. Registration for the courses opens from 0900 on Monday 8 December 2014.

WELCOME RECEPTION The Welcome Reception immediately follows the conference programme at 1900–1930 on Monday 8 December and will take place in the Exhibition area located in the Pickwick Suite, first floor.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

CPD Accreditation:	Credits attributed	Unique ref number
FIVE NATIONS CONFERENCE ON HIV AND HEPATITIS	10 Credits	90148
PRE-CONFERENCE CLINICAL COURSE	2 Credits	90148
PRE-CONFERENCE NURSES' COURSE	2 Credits	90148

Accommodation

Please note that the registration fee does **not** include accommodation. A list of hotels and rates is available on the BHIVA website (www.bhiva.org). Please note that **HotelMap** has been appointed the official conference accommodation bureau. HotelMap is a web-based service that provides live details of hotel deals directly from hotels near to our event venue. On booking, you will receive a hotel reservation booking reference number. Payment will need to be made by you, directly to the hotel.

Book online: www.bhiva.org · Queries: **HotelMap** · Tel: **0207 420 4987**

Cloakroom

A staffed Cloakroom is available at the Queen Elizabeth II Conference Centre. All belongings are left at the owner's risk. The Queen Elizabeth II Conference Centre and the British HIV Association do not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom areas.

Conference venue Queen Elizabeth II Conference Centre


Broad Sanctuary · Westminster · London SW1P 3EE · ☎ +44 (0)20 7222 5000 · 🌐 qeicc.co.uk

The conference venue is a short walk from Westminster or St James's Park underground stations. Please see the map for the location of these stations in relation to the Queen Elizabeth II Conference Centre. Westminster and St James's Park underground stations are easily accessible from King's Cross, St Pancras (Eurostar) and Victoria main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James's Park underground stations takes approximately 10 minutes and costs approximately £4.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either Heathrow or Gatwick Express take about 1 hour.

There are four car parks near to the conference venue. For further information please visit www.ncp.co.uk

Please note that the conference venue is located within the London Congestion Charge Zone.





CONFERENCE SPONSORS

AbbVie Limited

Abbott House, Vanwall Business Park
Maidenhead
Berkshire SL6 4XE



Boehringer Ingelheim Limited

Ellesfield Avenue
Bracknell
Berkshire RG12 8YS



Bristol-Myers Squibb Pharmaceuticals Limited

Uxbridge Business Park
Sanderson Road
Middlesex UB8 1DH



Gilead Sciences Limited

Granta Park
Great Abington
Cambridgeshire CB21 6GT



Janssen

50-100 Holmers Farm Way
High Wycombe
Buckinghamshire HP12 4EG



MSD Limited

Hertford Road
Hoddesdon
Hertfordshire EN11 9BU



CONFERENCE EXHIBITORS

Commercial

**Bristol-Myers Squibb
Pharmaceuticals HCV**

Cepheid

Hologic

Janssen HIV

Educational and Charitable

European AIDS Treatment Group (EATG)

UK Community Advisory Board (UK-CAB)


PRE-CONFERENCE COURSES

Pre-conference Clinical Course

Bristol-Myers Squibb Pharmaceuticals has supported the Five Nations Pre-conference Clinical Course by purchasing exhibition stand space and delegate places and has had no input into the selection of speakers or topics.

Pre-conference Nurses' Course

AbbVie, Gilead Sciences, Janssen and Roche have supported the Five Nations Pre-conference Nurses' Course by purchasing exhibition stand space and delegate places and have had no input into the course programme.



Exhibition opening times	
1145–2000	: Monday 8 December 2014
0800–1410	: Tuesday 9 December 2014

KEY TO EXHIBITORS

Stand 1	AbbVie
Stand 2	MSD
Stand 3	Bristol-Myers Squibb Pharmaceuticals (HCV)
Stand 4	European AIDS Treatment Group (EATG)
Stand 5	UK Community Advisory Board (UK-CAB)
Stand 6	Hologic
Stand 7	Cepheid
Stand 8	Gilead Sciences
Stand 9	Bristol-Myers Squibb Pharmaceuticals (HIV)
Stand 10	Janssen (HCV)
Stand 11	Janssen (HIV)



FIVE NATIONS PROGRAMME COMMITTEE

Dr Mark Nelson (Chair)	<i>Chelsea and Westminster Hospital, London, UK</i>
Dr Sanjay Bhagani (BHIVA)	<i>Royal Free Hospital, London, UK</i>
Professor Giovanni Guaraldi (SIMIT)	<i>University of Modena, Italy</i>
Dr Mark Hudson (BASL)	<i>Freeman Hospital, Newcastle, UK</i>
Dr Robert James (UK-CAB)	<i>Birchgrove, Brighton, UK</i>
Mr Damian Kelly (EATG)	<i>George House Trust, Manchester, UK</i>
Dr Ranjababu Kulasegaram (BHIVA)	<i>St Thomas' Hospital, London, UK</i>
Professor Karine Lacombe (ANRS)	<i>Hôpital Saint-Antoine, Paris, France</i>
Professor Clifford Leen (BHIVA)	<i>Western General Hospital, Edinburgh, UK</i>
Dr Alastair Miller (BHIVA)	<i>Royal College of Physicians, London, UK</i>
Dr Juan Macias (GEHEP)	<i>Hospital Universitario de Valme, Sevilla, Spain</i>
Dr Stefan Mauss (DAIG)	<i>Center for HIV and Hepatogastroenterology, Düsseldorf, Germany</i>
Dr Juan Antonio Pineda (GEHEP)	<i>Hospital Universitario de Valme, Sevilla, Spain</i>
Professor Lionel Piroth (ANRS)	<i>Centre Hospitalier Universitaire, Dijon, France</i>
Professor Jürgen Rockstroh (DAIG)	<i>University of Bonn, Germany</i>
Professor Gloria Taliani (SIMIT)	<i>Sapienza University of Rome, Italy</i>
Dr Andrew Ustianowski (BVHG)	<i>North Manchester General Hospital, UK</i>





Isabelle Andrieux-Meyer MD is an HIV and viral hepatitis specialist with Médecins sans Frontières. She works on clinical and programmatic issues relating to access to diagnostics and antiretroviral therapy, and viral hepatitis oral treatments in resource-limited settings. She serves also as Médecin Visitant at Geneva University Hospital, at the Infectious Disease Consultation.

Sanjay Bhagani is a Consultant Physician in Infectious Diseases and HIV Medicine at the Royal Free London NHS Foundation Trust. He has a special interest in the management of complex HIV infection, including difficult opportunistic infections and the management of viral hepatitis in HIV-infected patients.

Christoph Boesecke MD completed his medical studies at Charité University in Berlin, Germany. He received his Doctorate in Medicine from the University of Hamburg, Germany for his research on acute HIV infection. He held a 2-year postgraduate position studying integrase inhibitors in acute and chronic HIV infection at the National Centre in HIV Epidemiology and Clinical Research (now the Kirby Institute) in Sydney, Australia. He is currently working as an Infectious Diseases Specialist and Clinical Research Fellow at the University of Bonn, Germany. His main areas of research are focused on co-morbidities and co-infections in HIV, particularly acute hepatitis C.

Patrice Cacoub is Professor in Internal Medicine at the Pierre and Marie Curie University (PMCU) in Paris, France. He is also Head of the Department of Internal Medicine at La Pitié-Salpêtrière Hospital in Paris. His research focuses on autoimmune diseases, HCV, HBV, HIV, peripheral neuropathies, anaemia and vascular medicine, and he has authored more than 500 research publications, 52 books and 120 CME publications in these fields. Professor Cacoub is currently a reviewer for many top-ranked journals. The recipient of several awards, including the Fred Siguier Award of the French National Society of Internal Medicine, Professor Cacoub has been involved in the development of a number of national and international guidelines, clinical trials and initiatives to improve clinical care, particularly in HCV treatment and HIV/HCV co-infection, and in peripheral arterial disease.

Janet Catt MSc RGN, Independent Non-medical Prescriber, has had a varied nursing experience that has included oncology, haematology, palliative care and health visiting. Since 2008 she has been a Lead Nurse Specialist Practice at the Royal Free Hospital, London where she manages a team of clinical nurse specialists and leads on the development of the nursing service. As part of her role, she also researches local epidemiology in order to develop ways to improve patient pathways. She is a founder member of the steering group for the Interactive Summit on Hepatitis and sits on the London Joint Working Group for Substance Misuse and Hepatitis C. She is a regular speaker at international conferences.

Kate Childs is currently undertaking a PhD on HIV and hepatitis as an NIHR Doctoral Fellow at King's College London. She attained her undergraduate degree from St Hugh's College, Oxford and medical qualification from University College Hospital, London. She completed her specialist training in genitourinary medicine at King's College Hospital where she has been involved in the HIV/hepatitis co-infection clinic since 2009.

Amanda Clements MSc, PGCE, PGDip is an Advanced Nurse Practitioner, Independent Non-medical Prescriber and Hepatology Nurse Consultant for the South West Liver Unit, Derriford Hospital, Plymouth. She has been in post for over 14 years and during this time, the hepatology nursing service has rapidly expanded, reflecting the growth of liver disease. Her particular area of interest is promoting and developing end-of-life and long-term condition management for individuals and their care-givers, affected by end-stage liver disease. Amanda is chief editor for the BASL Nurse e-learning toolkits and she has been actively involved with the BASL Nurse Forum since it first began.

Douglas T Dieterich is currently Professor of Medicine in the Division of Hepatology, New York, NY with a triple appointment in the divisions of Liver Disease, Gastroenterology and Infectious Diseases. He is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic hepatitis B and C. Professor Dieterich is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis. Widely published, he is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver.



Graham Foster is the Professor of Hepatology at Queen Mary University of London and a consultant at Barts Health in East London. He trained in medicine at Oxford and London Universities and completed a PhD in molecular biology in 1992. He has a long-standing interest in the management of chronic viral hepatitis and runs a clinical research programme studying the natural history of viral hepatitis, its impact upon individuals and their communities, and novel therapies for this disease. He leads a national study investigating community screening for viral hepatitis and supervises a laboratory research programme investigating novel replication models for hepatitis C. He is the editor of *Journal of Viral Hepatitis* and has published widely in the field of viral liver disease. He is a past President of BASL, Vice Chair of the UK Department of Health Advisory Group on Hepatitis, and a member of a number of patient advocacy groups.

Diego Garcia Morcillo is currently Chair of a community centre for HIV/AIDS and other STIs in Seville, Spain and also the Coordinator of the Spanish CAB-FEAT. He lives with HIV and hepatitis C and since 2009, he has been a community representative on the EACS co-infection panel.

Ricky Gellissen has worked in HIV nursing since the early 1990s. Since 2008 he has been an HIV and hepatitis co-infection Clinical Nurse Practitioner, working across the HIV and Hepatology departments. He holds clinics in both departments seeing HIV or hepatitis mono-infected patients, but his primary focus is on managing HCV treatments for the HIV/HCV co-infected patients, including those on the NHS England-funded expanded-access programme.

Patrick Ingiliz is a specialist in Internal Medicine and Infectious Diseases. He is a consultant at the Medical Center for Infectious Diseases in Berlin. His clinical research projects are focused on acute hepatitis C infection, liver fibrosis progression and steatohepatitis in HIV infection. He is actively involved in numerous trials on directly acting agents against hepatitis C in mono- and co-infected subjects.

Robert James is a sessional lecturer at the School of Law, Birkbeck College, and a patient rep at the HIV clinic in Brighton UK. He is the community member of the BHIVA Hepatitis Coinfection Guidelines writing group.

Patrick Kennedy is a Senior Lecturer and Consultant Hepatologist at Barts and The London School of Medicine and Dentistry. His research focus is in hepatitis B and particularly immunopathogenesis of disease in young people. In addition, he has served on the NICE clinical guideline development group for chronic hepatitis B and most recently was a member of the NICE Quality Standards committee.

Ranjababu Kulasegaram is a Consultant in HIV/GU Medicine at St Thomas' Hospital and leads the HIV Treatment Advice Clinic. He has special interests in HIV/hepatitis, haemophilia/HIV infection, HIV/neurocognitive function and HIV inpatient management. He is committed to enhancing BHIVA's educational activities through his involvement as Vice Chair of the BHIVA Educational and Scientific subcommittee, member of the Conferences subcommittee and E-Learning working group. He is also Chair of the BHIVA Hepatitis Society and an examiner for the Diploma in HIV Medicine.

Karine Lacombe MD, PhD is Associate Professor at the Medical School of the Pierre and Marie Curie University, Paris, attached to the Infectious and Tropical Diseases department of Saint-Antoine Hospital, Paris. She is involved in clinical research in Europe, Sub-Saharan Africa and Vietnam on the issues of HIV-chronic hepatitis B and C, as well as co-morbidities associated with the use of antiretrovirals.

Maud Lemoine is a Clinical Senior Lecturer and Honorary Consultant in Hepatology at St Mary's Hospital, Imperial College London. She completed her medical degree and a PhD in physiology and physiopathology in Paris. She also graduated in political sciences from the Institute of Political Studies in Paris. She has spent the last two years at the Medical Research Council (MRC) Laboratories in The Gambia, West Africa running the PROLIFICA project (EU-FP7) on HBV and liver cancer. She is the Chief investigator of the multicentric European study on metabolic liver disease in HIV (ECHAM study funded by ANRS-HIVERA). She is member of the WHO scientific advisory board for the development of hepatitis C guidelines and a member of the French Research Agency on HIV/AIDS and viral hepatitis (ANRS).



Dean Linzey is Nurse Consultant for viral hepatitis at the Royal Berkshire Hospital. He is a counsellor and holds an MA in Psychoanalytic Studies. He is an Independent Non-medical Prescriber and Chair of the South regional Viral Hepatitis Nurses group. He has focused on blood-borne viruses for more than 20 years, working in UK clinics and abroad. He developed HIV counselling training for the UN in India and has worked for the British Council, CDC and Médecins Sans Frontières in Russia, Ukraine, Kenya, Tanzania, Uganda and Malawi. His particular interest is in community capacity building in relation to blood-borne viruses. Dean developed the BBV Champions project in 2010 for which he was awarded Gastrointestinal Nurse of the year in 2012; he was also awarded 'Healthcare worker of the year' in the 2012 Pride of Reading awards.

Luís Mendão concluded his studies in biochemistry in 1983 at the Pierre and Marie Curie University, Paris. He is currently Chair of GAT-Pedro Santos, an NGO founded in 2001 that works in the areas of prevention, early diagnosis, and treatment and care of HIV/AIDS and related diseases for most at-risk groups. He is also the founder and a member of the Board of Directors of the AntiProhibitionist Association, SOMA-APA. He represents Portugal in the Civil Society Forum on HIV/AIDS at the European Commission, is a member and Vice Chair of the European AIDS Treatment Group (EATG) and is also on the Steering Committee of the HIV Portugal Initiative. In the last 10 years, he has been community consultant of the Regional Office of the World Health Organization Europe (WHO Europe), EMCDDA and ECDC. Luís Mendão was diagnosed with HIV and HCV in 1996.

Nicolás Merchante works at the Infectious Diseases unit of the Hospital Universitario de Valme, Seville. As a clinical investigator, he has focused on the natural history of cirrhosis, end-stage liver disease and hepatocellular carcinoma in the setting of HIV/HCV-co-infected individuals. He is the coordinator of the GEHEP multicentre collaborative national cohort of hepatocellular carcinoma in HIV-infected patients in Spain.

Amanda Mocroft has worked in HIV epidemiology and biostatistics based at University College London since 1993. Particular interests include cohort studies and long-term outcomes of HIV infection, including mortality and non-AIDS-defining events, such as renal disease and malignancies. She is the co-PI of EuroSIDA, one of the largest multinational European cohorts of HIV-infected persons, and is also involved in numerous other cohort studies, including Data on Adverse Events (D:A:D), Antiretroviral Therapy Cohort (ART-CC), COHERE and MATCH. With over 200 publications, she has extensive experience with data collection, design and analyses of cohort studies, and nested case control studies using sample repositories.

Mark Nelson is a Consultant Physician at the Chelsea and Westminster Hospital, London. He trained at Jesus College, Cambridge and Westminster Hospital Medical School from where he qualified in 1986. He is presently the lead for HIV in-patient and day-case care and is an Adjunct Professor in Human Immunodeficiency Virology at Imperial College Medical School where he is also the deputy senior tutor. He is now devoting most of his charitable time to the Green Shoots Foundation where he is establishing HIV treatment networks in Burma and Vietnam. He has been awarded a visiting professorship at the Aga Khan Hospital, Nairobi, Kenya and Mbale Medical School, Uganda and most recently, was awarded the Certificate of Merit by the Government of Vietnam.

Emma Page is currently a locum Consultant in GUM and Virology at Leeds Teaching Hospitals Trust with a subspecialty interest in HIV and hepatitis co-infection. She trained at Chelsea and Westminster Hospital and has an MD(Res) from Imperial College London in the immunology of HIV and hepatitis C co-infection.

Jean-Michel Pawlotsky MD, PhD is Professor of Medicine at the University of Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and Delta and of the Department of Virology at the Henri Mondor University Hospital, Créteil, France. He is also Director of the Viruses, Immunity and Cancers Academic Department, INSERM U955. He was Secretary General of EASL, an Associate Editor of Hepatology and is currently an Associate Editor of Gastroenterology. He has published over 450 articles and book chapters and regularly lectures at international meetings.

Carlo-Federico Perno is Professor of Virology at the University of Rome 'Tor Vergata', and Director of the Unit of Molecular Virology at the Tor Vergata University Hospital, Rome. He is also a Consultant in Clinical Virology at the Spallanzani Hospital for Infectious Diseases, Rome. He gained his MD from the University of Rome. During his time as a Research Fellow at the National Cancer Institute, Bethesda (1986–1989), he collaborated in the discovery and clinical application of the first antiviral drugs used in the therapy of HIV infection, including zidovudine, zalcitabine, stavudine and didanosine. He has published more than 400 international scientific articles and in 2001, was presented with a Descartes Award for excellence in the antiviral field by the European Community. His major expertise is in antiviral therapy, clinical interpretation and therapeutic application of antiviral resistance testing and he leads a group of internationally recognised researchers.



Joe Phillips has worked in the field of HIV for around 10 years, both as a nurse and within the voluntary sector. After starting his career at the Infectious Diseases Unit, North Manchester Hospital he worked in the North-west as both an HIV and hepatitis C Specialist Nurse. He is currently employed as a Nurse Practitioner at 56 Dean Street in central London and has a specialist interest in HIV/hepatitis C co-infection, especially in relation to gay men who use chemo for sex.

Juan A Pineda earned his medical degree and PhD at the University of Seville. He completed his training in the Virgen del Rocío University Hospital in Seville and in the Presbyterian Hospital, Pittsburgh, USA. He is a Consultant in viral hepatitis and HIV infection in the Infectious Diseases Unit of the Valme University Hospital, Associate Professor of Medicine at the University of Seville, and Head of the Viral Hepatitis Study Group of the Spanish Society for Infectious Diseases and Clinical Microbiology.

Lionel Piroth has been involved in clinical care and research in HIV and hepatitis viruses in France since the mid-1990s. He is Professor of Infectious Diseases at the University of Burgundy and Physician at the Dijon Hospital, and also actively participates in trials of antiretrovirals and other anti-infective agents. He has been a co-author on the French recommendations for the management of hepatitis co-infection in people living with HIV.

Massimo Puoti is a Specialist in Gastroenterology and Infectious Disease and since November 2010 has been Director of the Infectious Diseases Department of the AO Ospedale Niguarda Cà Granda, the largest hospital in Milan, Italy. His main fields of research are hepatitis viruses and HIV infection.

Jürgen Rockstroh MD is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn, Germany. In addition to his clinical practice, Professor Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV and hepatitis co-infection.

Caroline Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is Director of the National Institutes for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, a partnership between UCL, Public Health England (PHE) and the London School of Hygiene and Tropical Medicine. She has worked for many years on the analysis of large observational HIV databases with a particular interest in raising awareness of the biases inherent in these databases; she is the principal investigator on the UK CHIC Study, the principal statistician on the D:A:D Study, co-principal investigator on the POPPY Study, and has worked with many other research groups in the UK and elsewhere.

Vincent Soriano MD PhD received his medical degree in Barcelona, and subsequently specialised in Internal Medicine. After a post-doctoral post at the FDA, Bethesda, USA, he returned to Spain and joined the Infectious Diseases Department at Hospital Carlos III in Madrid. His expertise is mainly focused on HIV and viral hepatitis.

Gloria Taliani DM, PhD is Professor of Infectious Diseases and Director of the School of Tropical Medicine, Sapienza University of Rome. She previously held the position of Director of the Clinic of Infectious Diseases, University of Florence. Her main area of scientific interest is viral hepatitis.

Andrew Ustianowski is a Consultant Physician in Infectious Diseases and Tropical Medicine at the Regional Infection Unit, North Manchester General Hospital, which has a cohort of around 2000 HIV-positive individuals. He has been part of guideline writing groups for BHIVA and other bodies, is chair of the British Viral Hepatitis Group, and is on the national CRGs for hepatitis C and infectious diseases. He also lectures widely on HIV, hepatitis and related topics, and is part of several national and international educational steering groups. He graduated from Guy's Hospital, London, and subsequently trained in Infectious Diseases, HIV and General Medicine in the London region.

DAKLINZA® (daclatasvir)**PRESCRIBING INFORMATION.** See Summary of Product Characteristics before prescribing.

PRESENTATION: 30mg/60mg (daclatasvir dihydrochloride) film coated tablets **INDICATION:** Treatment of chronic hepatitis C virus (HCV) infection in adults, in combination with other medicinal products. **DOSAGE: Adults:** The recommended dose of Daklinza is 60 mg once daily. Daklinza must be administered in combination with other medicinal products. For genotype 1 or 4 without cirrhosis, Daklinza+sofosbuvir is recommended for 12 weeks. For genotype 1 or 4 with compensated cirrhosis, Daklinza+sofosbuvir is recommended for 24 weeks. For genotype 3 with compensated cirrhosis and/or treatment-experienced, Daklinza+sofosbuvir+ribavirin is recommended for 24 weeks. For genotype 4, Daklinza+peginterferon alfa+ribavirin is recommended for 24-48 weeks. The Summary of Product Characteristics (SmPC) for the other medicinal products in the regimen should also be consulted before initiation of therapy with Daklinza. The safety and efficacy of Daklinza in children and adolescents aged below 18 years have not yet been established.

ADMINISTRATION: Daklinza is to be taken orally with or without meals. Patients should be instructed to swallow the tablet whole. **CONTRAINDICATIONS:** Hypersensitivity to the active substance or to any of the excipients. Coadministration with medicinal products that strongly induce cytochrome P450 3A (CYP3A4) and P-glycoprotein transporter (P-gp) and may lead to lower exposure and loss of efficacy of Daklinza. These include but are not limited to phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John's wort. **WARNINGS AND PRECAUTIONS:** Must not be administered as monotherapy. Due to limited experience, uncertainties remain regarding the most effective way to use Daklinza for treatment in patients with genotype 1 infection and compensated cirrhosis, genotypes 2 and 3 infection, and how to tailor regimens according to important factors potentially affecting the virological response. The combination of Daklinza and sofosbuvir is expected to yield similar activity for genotype 4 as observed for genotype 1, based on in vitro antiviral activity and available clinical data with Daklinza in combination with peginterferon and ribavirin. Daklinza has not been studied in patients with HCV genotypes 5 and 6, and no regimen recommendation can be given. The efficacy of Daklinza as part of a retreatment regimen in patients with prior exposure to a NS5A inhibitor has not been established. The safety and efficacy of Daklinza in the treatment of HCV infection in patients with decompensated liver disease, pre-, peri-, or post-liver transplant or other organ transplant patients have not been established. Daklinza contains lactose. Patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

DRUG INTERACTIONS: Dose adjustment of Daklinza is recommended when coadministered with moderate inducers and strong inhibitors of CYP3A4 and P-gp. Caution should be used if the medicinal product has a narrow therapeutic range (see SmPC). **PREGNANCY AND LACTATION:** Daklinza should not be used during pregnancy or in women of child-bearing potential not using effective contraception. Use of highly effective contraception should be continued for 5 weeks after completion of Daklinza therapy. It is not known whether Daklinza is excreted in human milk. Mothers should be instructed not to breastfeed if they are taking Daklinza. No data is available on the effect of Daklinza on fertility.



UNDESIRABLE EFFECTS: In combination with sofosbuvir most frequent: fatigue, headache and nausea; in combination with peginterferon alfa and ribavirin most frequent: fatigue, headache, pruritus, insomnia, influenza-like illness, dry skin, nausea, decreased appetite, alopecia, rash, asthenia, irritability, myalgia, anaemia, pyrexia, cough, dyspnoea, neutropenia, diarrhoea and arthralgia; in combination with sofosbuvir with or without ribavirin very common ($\geq 1/10$): headache, nausea, fatigue, common ($\geq 1/100$ to $<1/10$): anaemia, decreased appetite, depression, anxiety, insomnia, dizziness, migraine, hot flush, cough, dyspnoea, exertional dyspnoea, nasal congestion, diarrhoea, upper abdominal pain, constipation, flatulence, gastroesophageal reflux disease, dry mouth, vomiting, pruritus, dry skin, alopecia, rash, arthralgia, myalgia, irritability. See SmPC for further details. **LEGAL CATEGORY: POM. MARKETING AUTHORISATION NUMBER AND BASIC NHS PRICE:** 30 mg, 28 film-coated tablets (EU/1/14/939/002) £8,172.61; 60 mg, 28 film-coated tablets (EU/1/14/939/004) £8,172.61 **MARKETING AUTHORISATION HOLDER:** Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH. Tel: 0800 731 1736. **DATE OF PREPARATION:** November 2014 1392UK14PR09947-01

WITH DAKLINZA® AS YOUR ALLY, YOU CAN ACHIEVE...

**NOW
APPROVED**

THE LONG-AWAITED RESPONSE

Introducing Daklinza, a potent, pan-genotypic (in vitro), NS5A inhibitor with clinical efficacy in genotypes 1-4, which cures* the vast majority† of patients with chronic hepatitis C virus (HCV) including:‡

ADVANCED FIBROSIS****PI FAILURES****GENOTYPE 3**

Daklinza is indicated in combination with other medicinal products for the treatment of chronic HCV infection in adults.¹ Daklinza must not be administered as monotherapy.¹

* Cure corresponds to an undetectable HCV RNA at 24 weeks (lower limit of detection <15 IU/ml, SVR_{12}) which has a 99% concordance with SVR_{12} as the definitive cure of HCV infection.³

† Vast majority based on UK epidemiology corresponding to 90% of HCV patients with genotype 1 or genotype 3.⁴

** Advanced fibrosis is defined as a score $\geq F3$ based on FibroTest data. The METAVIR score was derived from the FibroTest Score and classified according to the manufacturer's instructions (www.biopredictive.com); patients with a score of F4 were required to have no evidence of cirrhosis on the basis of a liver biopsy.²

‡ Percentage of patients achieving SVR_{12} after 12 or 24 weeks of Daklinza combined with sofosbuvir across subgroups and treatment arms (+/- ribavirin).^{1,2} Patients who had missing data at follow-up week 12 were considered responders if their next available HCV RNA value was $<LOQ$.¹

Adverse events should be reported.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to

Bristol-Myers Squibb Pharmaceuticals Ltd.

Medical information on 0800 731 1736,

medical.information@bms.com**References:**

1. DAKLINZA (daclatasvir) Summary of Product Characteristics. DAKLINZA Bristol-Myers Squibb Company.
2. Sulikowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med*. 2014;370:211-221.
3. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. *J Hepatol*. 2014;60:392-420.
4. Public Health England. Hepatitis C in the UK 2014. Available at: <https://www.gov.uk/government/publications/hepatitis-c-in-the-uk> (accessed November 2014).

**Bristol-Myers Squibb**

© 2014 Bristol-Myers Squibb Company 1392UK14PR09592-01 November 2014
DAKLINZA® is a registered trademark of Bristol-Myers Squibb and its affiliates



NEW

Daklinza®
(daclatasvir)